Kyverna Therapeutics, Inc. (KYTX) Dividend History

Company News

• Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf

  Grabar Law Office is investigating claims on behalf of long-term shareholders of Archer-Daniels-Midland, Driven Brands, Kyverna Therapeutics, and Mercury Systems, as their respective securities fraud class action complaints have survived motions to dismiss.

  GlobeNewswire Inc.

  Featured Companies: ADM DRVN MRCY
• Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

  Grabar Law Office is investigating claims on behalf of shareholders of Fluence Energy, Kyverna Therapeutics, Mercury Systems, and Sage Therapeutics, alleging breaches of fiduciary duties by certain officers and directors.

  GlobeNewswire Inc.

  Featured Companies: FLNC MRCY SAGE
• CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

  The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

  GlobeNewswire Inc.

  Featured Companies: ACLX ALLO DTIL IPSC RNAC SANA
• Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

  Kyverna Therapeutics, Inc. (KYTX) is facing a class action lawsuit regarding its February 2024 initial public offering. The lawsuit alleges that the company and its underwriters made materially false and/or misleading statements in the offering documents.

  GlobeNewswire Inc.
• KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

  A class action lawsuit has been filed against Kyverna Therapeutics, Inc. (KYTX) for alleged violations of federal securities laws related to its IPO in February 2024. The lawsuit claims the company failed to disclose adverse data from one of its clinical trials in its offering documents.

  GlobeNewswire Inc.